Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Evofem raises $20mm through private placement concurrent with Neothetics merger

Executive Summary

Concurrent with its merger with Neothetics Inc., Evofem Biosciences Inc. (the surviving company) brought in $20mm through a private placement of 9.7mm Neothetics common shares to Invesco Asset Management, which also received purchase warrants for 159mm Evofem common shares. In a separate transaction, the two firms announced they'd combine in a reverse stock swap to create a women's health-focused company. Proceeds from this financing will help support development of Evofem's lead candidate, the Phase III Amphora (L-lactic acid, citric acid, and potassium bitartrate), hormone-free, on-demand vaginal contraceptive gel.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies